TABLE 9.
Author(s) | Method | Results |
---|---|---|
Duan et al19 | qPCR confirmed by plaque reduction assay | 6.4% resistance in immunocompetent patients with herpetic keratitis |
Stránská et al79 | ELVIRA HSV screening assay | 0.27% resistance in immunocompetent and 7% resistance in immunocompromised patients |
Danve-Szatanek et al15 | Chessboard technique | 0.3% resistance in immunocompetent and 3.6% resistance in immunocompromised patients, with highest resistance in bone marrow transplant (10.9%) |
Reyes et al71 | Plaque reduction assay | 0.1% resistance in immunocompetent patients |
Gnann et alD | Plaque reduction assay | 5.6% resistance in immunocompromised patients |
Christophers et al13 | Plaque reduction assay | 0.1–0.7% resistance in immunocompetent and 6.3% resistance in immunocompromised patients |
ELVIRA = enzyme linked virus inhibitor reporter assay; qPCR = quantitative polymerase chain reaction.